This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Onconetix Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Onconetix's earnings have been declining at an average annual rate of -72.2%, while the Biotechs industry saw earnings growing at 13.6% annually. Revenues have been growing at an average rate of 160.5% per year.
Belangrijke informatie
-72.2%
Groei van de winst
-32.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | -14.6% |
| Inkomstengroei | 160.5% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -3,629.3% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Geen updates
Recent updates
Opbrengsten en kosten
Hoe Onconetix geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -53 | 15 | 0 |
| 31 Mar 24 | 1 | -46 | 15 | 1 |
| 31 Dec 23 | 0 | -37 | 13 | 2 |
| 30 Sep 23 | 0 | -18 | 10 | 3 |
| 30 Jun 23 | 0 | -17 | 9 | 4 |
| 31 Mar 23 | 0 | -14 | 10 | 5 |
| 31 Dec 22 | 0 | -14 | 9 | 4 |
| 30 Sep 22 | 0 | -12 | 8 | 3 |
| 30 Jun 22 | 0 | -9 | 6 | 2 |
| 31 Mar 22 | 0 | -6 | 3 | 2 |
| 31 Dec 21 | 0 | -4 | 2 | 1 |
| 30 Sep 21 | 0 | -3 | 2 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 1 |
Kwaliteitswinsten: J4T is currently unprofitable.
Groeiende winstmarge: J4T is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: J4T is unprofitable, and losses have increased over the past 5 years at a rate of 72.2% per year.
Versnelling van de groei: Unable to compare J4T's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: J4T is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-22.6%).
Rendement op eigen vermogen
Hoge ROE: J4T's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.